Oxford StemTech produces human stem cells for research and drug discovery.
The full potential of induced pluripotent stem cells (iPSC) is not being realised because current reprogramming methods are labour-intensive, low-throughput and costly.
StemTech has developed a novel method that drastically reduces the cost and hugely increases the scale of reprogramming to produce the highest quality stem cell lines. Our ability to rapidly produce iPSCs at scale allows precision medicine research and drug discovery on large cohorts of patients. At StemTech, we would like to support your goals to better understand disease, discover novel drug targets and get medicines that work into clinic.
Company Details
- Employees
- 7
- Founded
- -
- Address
- The Oxford Science Park, Hayakawa Building,united Kingdom
- Industry
- Biotechnology
- Website
- https://www.oxfordstemtech.com
- Keywords
- Reprogramming, iPSC technology, Precision medicine, Drug discovery, Disease modelling, Neuroscience, High throughput screening, Cell-based assay.
- HQ
- Oxford, Oxfordshire
Oxford Stemtech Questions
Oxford Stemtech's website is https://www.oxfordstemtech.com
Oxford Stemtech's LinkedIn profile is https://uk.linkedin.com/company/oxford-stemtech
Oxford Stemtech has
7 employees.
View email and phone details for 7
employees at Oxford Stemtech.
Oxford Stemtech's industry is
Biotechnology
Oxford Stemtech's top competitors are
Granza Bio (Yc W24),
Oxford Endovascular Ltd.,
Biolligence,
Neuro-Bio Ltd,
Maxwell Biosystems,
Scripta Therapeutics,
Exscientia,
London Stone,
Oxford Biotherapeutics,
Dark Blue Therapeutics.
Oxford Stemtech's categories are Biotechnology
Oxford Stemtech's founding year is 2020
